Domestic listing status and medical insurance price of Glasgib/Grasgib

Glasdegib is a Hedgehog signaling pathway inhibitor that is mainly used to treat acute myeloid leukemia (AML), especially in patients who are older or unable to tolerate standard chemotherapy. The drug was developed by Pfizer (Pfizer) and was approved by the US FDA for marketing in 2018 under the trade name Daurismo. However, Glasgib has not yet been approved for marketing in China, so domestic hospitals and pharmacies cannot provide the drug.

Since it is not listed in the country, Glassgib has not yet entered China's medical insurance directory. Generally, after imported drugs are marketed in China, they need to be approved by the National Medical Products Administration (NMPA) and complete relevant clinical trials to ensure the safety and effectiveness of the drugs. Even if approved, drugs entering the medical insurance catalog still need to go through medical insurance negotiations, involving price adjustments and payment standards. Therefore, the current medical insurance coverage situation in Glassgibb is still unclear, and the specific timetable has not yet been announced.

Although Glasgib cannot be purchased directly in China, some patients can obtain it through cross-border drug purchase. For example, the drug may be sold in pharmacies in regions such as Europe. According to market conditions, the overseas price of Glass Gibb is relatively high. The common specification is 100mg × 30 tablets. The price per box may be around RMB 80,000 to RMB 90,000. The specific cost is affected by exchange rate fluctuations.

For patients who are in urgent need of the drug, they can consult through formal cross-border medical institutions or international pharmacies to ensure the legality and safety of the source of the drug. In addition, some international clinical trials may also provide drug access opportunities, and eligible patients may consider participating to reduce treatment costs. In the future, if Glassgib is successfully launched in China and entered into the medical insurance directory through medical insurance negotiations, the financial burden on patients is expected to be significantly reduced.

Reference materials:https://go.drugbank.com/drugs/DB11978